

# Michael Slade

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1481702/publications.pdf>

Version: 2024-02-01

38  
papers

654  
citations

687363

13  
h-index

580821

25  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1452  
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1851-1860.	2.0	135
2	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , 2017, 19, e12629.	1.7	75
3	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016, 101, e465-e468.	3.5	54
4	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 318-324.	2.0	54
5	Rapid detection of donor cell free DNA in lung transplant recipients with rejections using donor-recipient HLA mismatch. <i>Human Immunology</i> , 2017, 78, 342-349.	2.4	49
6	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1736-1743.	2.0	44
7	T Cellâ€“Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 648-653.	2.0	38
8	Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. <i>Bone Marrow Transplantation</i> , 2016, 51, 1561-1564.	2.4	34
9	Cardiomyopathy in patients after posttransplant cyclophosphamideâ€“based hematopoietic cell transplantation. <i>Cancer</i> , 2017, 123, 1800-1809.	4.1	27
10	Halfway there: the past, present and future of haploidentical transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1-6.	2.4	26
11	Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. <i>Bone Marrow Transplantation</i> , 2017, 52, 1623-1628.	2.4	21
12	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2047-2055.	2.0	18
13	HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. <i>Blood Advances</i> , 2018, 2, 3590-3601.	5.2	16
14	Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 898-901.	2.4	13
15	CD123 bi-specific antibodies in development in AML: What do we know so far?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101219.	1.7	12
16	The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 123-131.	2.0	9
17	Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. <i>Transfusion</i> , 2016, 56, 2331-2335.	1.6	7
18	Cytomegalovirus Viremia and Relapse after Haploidentical Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S320.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 769-771.	2.4	3
20	Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML. Case Reports in Hematology, 2017, 2017, 1-3.	0.4	3
21	Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 83, 1654-1658.	1.2	3
22	Can planned CD34+ stem cell boost prevent poor graft function after peripheral blood haploidentical hematopoietic transplantation?. Leukemia and Lymphoma, 2021, 62, 749-751.	1.3	3
23	Infectious Complications after Peripheral Blood (PB) Haploidentical Hematopoietic Cell Transplantation (haplo-HCT). Biology of Blood and Marrow Transplantation, 2016, 22, S176-S177.	2.0	1
24	Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated with Similar Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, S279.	2.0	1
25	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant – a retrospective study. Transplant International, 2020, 33, 1089-1098.	1.6	1
26	Impact of Donor Age and Relationship on Outcomes of Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. Blood, 2021, 138, 2924-2924.	1.4	1
27	The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation. Leukemia and Lymphoma, 2017, 58, 241-243.	1.3	0
28	A Small Cemetery. Journal of Clinical Oncology, 2021, 39, 2313-2313.	1.6	0
29	Cytomegalovirus (CMV) disease in peripheral blood (PB) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PT-Cy).. Journal of Clinical Oncology, 2016, 34, e18538-e18538.	1.6	0
30	Impact of KIR-ligand mismatch on outcomes after peripheral blood haploidentical hematopoietic cell transplantation.. Journal of Clinical Oncology, 2016, 34, 7051-7051.	1.6	0
31	Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1. Blood, 2016, 128, 4696-4696.	1.4	0
32	Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. Blood, 2016, 128, 4658-4658.	1.4	0
33	Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for Acute Leukemia and MDS. Blood, 2016, 128, 2278-2278.	1.4	0
34	Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation. Blood, 2016, 128, 4698-4698.	1.4	0
35	HLA Class II Epitope Mismatch Influences Relapse and Engraftment in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. Blood, 2018, 132, 4634-4634.	1.4	0
36	The Impact of Tocilizumab Treatment for Cytokine Release Syndrome on the Incidence of Blood Stream Infections after Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. Blood, 2021, 138, 1800-1800.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Comparison of Deep Whole Exome Versus Targeted Gene Sequencing for Assessment of Persistent Molecular Disease in Acute Myeloid Leukemia Samples. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
38	The impact of tocilizumab treatment for cytokine release syndrome on the incidence of early blood stream infections after peripheral blood haploidentical hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 0, , 1-7.	1.3	0